Over the past twenty years, steady progress in miniaturization of biological tests has enabled smaller patient samples, less reagent use, and higher speeds. The COVID pandemic, requiring billions of tests, has put huge pressure on suppliers of technology for manufacturing rapid, low-cost tests at the nanoliter and picoliter scale.

BioDot Inc, under its founder, has for decades been a leader in the evolution of technology for liquid transfer of samples and reagents from microliter to nanoliter to picoliter volumes. The company supplies liquid handling components, assemblies, and integrated sample processing systems to test kit manufacturers, R&D scientists, and clinical labs worldwide. The current installed base exceeds 5,500 units.

The dramatic need for COVD testing has given BioDot a fast launch into its growth strategy with sales roughly doubling in 2020. Senior managers that join the new team will face the simultaneous challenges of overwhelming short-term growth in existing markets and exciting opportunities in new markets with two fresh product lines.